HMA WGEO – Rapid Alert Form Counterfeit or illegal product found in the illegal supply chain

Reference:						
Date: 06/11/2018	Time:	Initials:				
Please complete sections 1 to 5 providing as much information as possible.						
1. REPORTING PERSON						
Name:	Position:					
Organisation:						
Address:						
Telephone No:			Ext: -			
e-mail address:						
2. PRODUCT DETAILS						
Product name: Macsy Bien-être						
Manufacturer: "M"; 617 DongFeng Dong Road; POB:510060						
Supplier: Macsybienetre / Biobuziness						
Legal status: Banned ☐ Counterfeit ☐Unlicensed ☒ Stolen ☐						
Dosage form: Box containing 6 powder bags (15 g) for oral use						
Strength: Only nutritional facts are mentioned						
Batch / lot no: MACSY COFFEE						
If yes to the above, advise batch destination country:						
Expiry date: 01.01.2021						
Language of packaging: English, (French in some sentences)						
Date of discovery: 01/08/2018						
Details of discovery: By customs in the luggage of a passenger from Ethiopia						
Analysed: YES ⊠ NO □						
If yes, result of analysis:						
The results of the analysis indicated that this product contains the following						
active substance: tadalafil 2,90 mg/g powder and caffeine 3,55 mg/g powder;						
or corresponding to 43,50 mg tadalafil & 53,25 mg caffeine per dosage form						
of 15 gram powder.						

Internet: YES ⊠ / NO □					
Internet: Macsy Bien-être (French)	Non internet, advise full				
URL: http://www.macsybienetre.com/listes-des-	details: List of names of				
distributeurs	distributors is mentioned on				
Website address: www.macsybienetre.com	the website in the countries				
	Germany, Belgium, Denmark,				
Other details: e-mail addresses:	the Netherlands, Ireland,				
macsybienetre@gmail.com,	United Kingdom, Switzerland,				
biobuziness@hotmail.fr	Norway, United States, Israel,				
	Australia, South Africa.				
Currency of payment: euro					
Has product reached patients/consumers? Yes					
4. RISK TO PUBLIC HEALTH					
Adverse reactions: YES ⊠ / NO □					
If yes, please advise details: risk of overdose and	risk of adverse reactions,				
particularly in patients with cardiovascular disease	es.				
Medical assessment details:					
5. NEED FOR PUBLICITY					
Are you making a public statement? YES / NO					
Are you issuing a press release? YES <pre> / NO</pre>					
Are you recalling product? YES ☐ / NO ☒					
If yes to any of the above, when do you intend to take action?					
6. DISSEMINATION					
Are you content for this Rapid Alert to be shared outside WGEO membership?					
YES ⊠ / NO □ (please see below)					
If yes, please specify which of the below you are content for this to be shared with					
(you may tick more than 1 box)					
Law Enforcement ⊠ Industry Security ☐ Trade Associations ⊠					
Traders ⊠ Other ☐ Please specify					
7. PHOTOGRAPH					
See pictures on the next page.					

3. DISTRUBUTION METHOD





